In December, Thousand Oaks Biologics announced the completion of a new round of financing of 1.5 billion yuan.

In April, we held "Conclusion of Civil Construction" ceremony for CCM2 in Haimen. 

In March, Thousand Oaks Biologics announced the completion of the C round financing of over 400 million yuan.

In February, JSBio signed a strategic cooperation intention agreement with Henlius.

In January, JSBio established a Korean joint venture with WSG Group in Korea for the serum-free cell culture medium business.

In May, JSBio was awarded by the China Vaccine Association for its outstanding contribution to the fight against COVID-19.

In November, JSBio's cell culture medium won the "Excellent Product Certificate" at the 22^nd China High-tech Fair.

In September, reached a strategic cooperation with Boan Bio, a subsidiary of Luye Pharma.

In July, fully cooperated with COVID-19 vaccine manufacturers.

In July, Thousand Oaks Biologics announced the completion of the Series B financing for 450 million yuan.

In May, a strategic cooperation with Hengrui Biopharma was inked on the development and supply of cell culture media.

In September, JSBio hosted the 4th Lanzhou Science and Technology Expo "One Belt, One Road -Biomedical Industry Development Forum".

In January, Thousand Oaks Biologics announced the completion of the A round financing for over 300 million yuan.

In October, JSBio reached a strategic partnership with BTI (Bioprocessing Research Institute under the Singapore Agency for Science, Technology and Research) to establish a CMC biomanufacturing process development joint laboratory.

In September, JSBio hosted the 3rd Lanzhou Science and Technology Expo "One Belt, One Road Biomedical Industry Development Forum"

In August, JSBio successfully passed the certification of ISO9001:2015，ISO14001:2015, and also ISO13485:2016.

In December, JSBio established the leading position of domestic culture medium based on the sales of culture medium.

In November, JSBio Shanghai R&D Center and Quality Analysis Center were established to more efficiently serve customers in East China.

In July, JSBio established a long-term supply strategic partnership with China's leading monoclonal antibody company – Genor Biopharma.

In July, JSBio assisted in the creation of the customer's antibody product GMA102 to pass the NMPA inspection.

In July, JSBio's serum-free cell culture medium products entered the Korean and Indian markets.

In April, JSBio's serum-free medium products entered the Chinese animal vaccine market.

In October, NMPA Class 1 medical device application got certified.

In December, "JSBio" was rated as "Gansu Famous Trademark" by the Provincial Administration of Industry and Commerce, and It was also rated as "Gansu Postdoctoral Innovation Practice Base" by the Provincial Department of Human Resources and Social Security.

In March, the basal media was recognized as substitution for global brand for domestic vaccine-manufacturing customers.

In August, JSBio’s proprietary media project was recognized by the National Science and Technology Enterprise Technology Innovation Fund.

In October, serum-free media made in China launched.

In August, ISO 9001, ISO 14001 certified.

In May, Perfusion platform established.

In October, serum-free media “made in China” launched.

In June, the largest cGMP DPM facility in China launched.

In March, the PR&D laboratory was in operation.

In June, JSBio was founded, and the laboratory with high industry requirements and the production workshop with cGMP standards began construction.